The molecular mechanism of IGF2BP3 promoting the malignant progression of lung cancer.
Lung cancer remains the leading cause of cancer-related mortality worldwide, underscoring the urgent need to elucidate its molecular mechanisms to improve treatment and prognosis.
APA
Wu C, Ma Y, et al. (2026). The molecular mechanism of IGF2BP3 promoting the malignant progression of lung cancer.. Cancer cell international, 26(1). https://doi.org/10.1186/s12935-026-04217-2
MLA
Wu C, et al.. "The molecular mechanism of IGF2BP3 promoting the malignant progression of lung cancer.." Cancer cell international, vol. 26, no. 1, 2026.
PMID
41634702
Abstract
Lung cancer remains the leading cause of cancer-related mortality worldwide, underscoring the urgent need to elucidate its molecular mechanisms to improve treatment and prognosis. Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) is aberrantly expressed in lung cancer and is closely associated with malignant progression. As a member of the m6A-modified RNA-binding proteins, IGF2BP3 recognizes and binds to m6A-modified RNAs, thereby regulating RNA stability and translation, ultimately influencing cell proliferation, tumorigenesis, and patient outcomes. This review aims to comprehensively explore the molecular mechanisms by which IGF2BP3 contributes to lung cancer development and progression, and to discuss its potential applications in diagnosis, prognostic assessment, and therapeutic strategies.
같은 제1저자의 인용 많은 논문 (5)
- Central antinociceptive activity of peripherally applied botulinum toxin type A in lab rat model of trigeminal neuralgia.
- SMARCA4 promotes lineage plasticity and enzalutamide resistance in prostate cancer by regulating PROX1 via H3K27 acetylation.
- Discovery of Bufalin as a Molecular Glue Degrader of NCAPG to Inhibit the Proliferation of Hepatoma Cells.
- Laparoscopic-Assisted Microwave Ablation for Splenic Hemangioma: A Case Report and Literature Review.
- Correction: Nutritional status and drug resistance in EGFR-mutant NSCLC: a retrospective cohort study on almonertinib efficacy.